• to reduce the chance of significant cardiovascular (coronary heart and blood vessel) problems in adults with style two diabetes and cardiovascular diseaseThis led Novo Nordisk to perform further more exploration into better dosages of semaglutide especially for weight administration.Only one company formally makes identify-model semaglutide wit